PRKAB1 and hepatocellular carcinoma: Nilotinib, the bcr‐abl kinase inhibitor, was approved for the treatment of imatinib‐resistant chronic myelogenous leukemia, and can induce autophagic cell death in HCC through AMPK activation [21].